Recursion Pharmaceuticals is a clinical-stage biotechnology company that is revolutionizing the field of drug discovery. Based in Salt Lake City, Utah, Recursion has developed a unique approach to identifying and designing new therapies using artificial intelligence (AI) models.

Their platform, known as the Recursion Operating System (Recursion OS), leverages machine learning algorithms to perform “experiments” within a vast database of genes within the complex maze of human biology. This allows Recursion to predict how certain chemical compounds would interact with genes, thereby identifying potentially promising drug candidates.

The company’s innovative approach has led to one of the largest, broadest, and deepest pipelines of any technology-enabled drug discovery company. Every program at Recursion is a product of their Recursion OS, and with every new discovery, their platform gets smarter, leading to pipeline growth.

In a groundbreaking collaboration, chipmaker Nvidia invested $50 million in Recursion Pharmaceuticals to speed up the development of the biotech firm’s AI models for drug discovery. This partnership will enable Recursion to use its biological and chemical datasets exceeding 23,000 terabytes to train its AI models on Nvidia’s cloud platform.